CyFlow CD18 FITC
| 品番 | AQ070678 | ||
|---|---|---|---|
| 抗体名 | Anti-Ms CD18 FITC,M18/2 | ||
| 包装単位 | 0.1 mg | ||
| 濃度 | 0.5 mg/ml | ||
| 容量 | 0.2 ml | ||
| 関連製品 (アイソタイプコントロール) |
- | ||
| 反応性|交差吸着 | Mouse | レーザー | Blue |
| 抗原 | CD18, b2 integrin | 最大蛍光波長 | 518 nm |
| クローン | M18/2 | 最大励起波長 | 490 to 495 nm |
| ホスト | Rat | 標識/Format | FITC |
| アイソタイプ | IgG2a | 研究分野 | Immunophenotyping | MHC |
| クローナリティ | monoclonal | 用途 | Flow cytometry |
Anti-Ms CD18 FITC,M18/2
特異性
The rat monoclonal antibody M18/2 recognizes mouse CD18 antigen, a 95 kDa type I transmembrane protein expressed on all leukocytes.
抗原情報
CD18 (integrin β2 subunit) forms heterodimers with four types of CD11 molecule to constitute leukocyte (β2) integrins: αLβ2 (CD11a/CD18, LFA-1), αMβ2 (CD11b/CD18, Mac-1, CR3), αXβ2 (CD11c/CD18) and αDβ2 (CD11d/CD18). In most cases, the response mediated by the integrin is a composite of the functions of its individual subunits. These integrins are essential for proper leukocyte migration, mediating intercellular contacts.
利用方法
The reagent is designed for Flow Cytometry analysis. Suggested working usage is 3 µg/ml. Indicated dilution is recommended starting point for use of this product, but working concentrations should be validated by the investigator.
保存方法
Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
安定性情報
Do not use after expiration date stamped on vial label.
レファレンス
• Abraham C, Miller J: Molecular mechanisms of IL‑2 gene regulation following costimulation through LFA‑1. J·Immunol. 2001·Nov·1; 167(9):5193‑201. <·PMID:·11673532·>
• Avni O, Pur Z, Yefenof E, Baniyash M: Complement receptor 3 of macrophages is associated with galectin‑1‑like protein. J·Immunol. 1998·Jun·15; 160(12):6151‑8. <·PMID:·9637533·>
• Barlow SC, Langston W, Matthews KM, Chidlow JH Jr, Kevil CG: CD18 deficiency protects against multiple low‑dose streptozotocin‑induced diabetes. Am·J·Pathol. 2004·Dec; 165(6):1849‑52. <·PMID:·15579429·>
• Cullere X, Lauterbach M, Tsuboi N, Mayadas TN: Neutrophil‑selective CD18 silencing using RNA interference in vivo. Blood. 2008·Apr·1; 111(7):3591‑8. <·PMID:·18216298·>
• Sakurai E, Taguchi H, Anand A, Ambati BK, Gragoudas ES, Miller JW, Adamis AP, Ambati J: Targeted disruption of the CD18 or ICAM‑1 gene inhibits choroidal neovascularization. Invest·Ophthalmol·Vis·Sci. 2003·Jun; 44(6):2743‑9. <·PMID:·12766082·>
• Sanchez-Madrid F, Simon P, Thompson S, Springer TA: Mapping of antigenic and functional epitopes on the alpha‑ and beta‑subunits of two related mouse glycoproteins involved in cell interactions, LFA‑1 and Mac‑1. J·Exp·Med. 1983·Aug·1; 158(2):586‑602. <·PMID:·6193226·>
• Varga G, Balkow S, Wild MK, Stadtbaeumer A, Krummen M, Rothoeft T, Higuchi T, Beissert S, Wethmar K, Scharffetter-Kochanek K, Vestweber D, Grabbe S: Active MAC‑1 (CD11b/CD18) on DCs inhibits full T‑cell activation. Blood. 2007·Jan·15; 109(2):661‑9. <·PMID:·17003381·>
• Watts GM, Beurskens FJ, Martin-Padura I, Ballantyne CM, Klickstein LB, Brenner MB, Lee DM: Manifestations of inflammatory arthritis are critically dependent on LFA‑1. J·Immunol. 2005·Mar·15; 174(6):3668‑75. <·PMID:·15749905·>
• Zahalka MA, Naor D: Beta 2‑integrin dependent aggregate formation between LB T cell lymphoma and spleen cells: assessment of correlation with spleen invasiveness. Int·Immunol. 1994·Jun; 6(6):917‑24. <·PMID:·7522049·>
• Zahalka MA, Okon E, Naor D: Blocking lymphoma invasiveness with a monoclonal antibody directed against the beta‑chain of the leukocyte adhesion molecule (CD18). J·Immunol. 1993·May·15; 150(10):4466‑77. <·PMID:·8097756·>
Available Safety Data Sheets
CyFlow™ monoclonal antibodies SDS CA EN